Toby Maher, MD
Pulmonary Disease · Los Angeles, CANPI 1982221958
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,121,731 of the $1,319,767 with a category attached, or 85.0%. 23 manufacturers reported payments, led by AstraZeneca at 49.1% of the total. Reporting peaked in 2021 at $495,360 and has fallen 50.2% since, to $246,706 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $3384.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$648K
- Boehringer Ingelheim International GmbH$244K
- Daiichi Sankyo Inc.$168K
- Boehringer Ingelheim$65K
- GSK$36K
- United Therapeutics Corporation$26K
- plus $132K from 17 others
Across 234 payments — averaging $112,762 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$25.7M
- Boehringer Ingelheim$252K
- E.r. Squibb & Sons, L.L.C.$128K
- Insmed, Inc.$69K
- Roche Products Limited$65K
- GSK$60K
- plus $146K from 6 others
What the payments were for
- Royalty or licence$6130%
- Consulting fees$1,121,73185%
- Speaking & faculty fees$114,3659%
- Travel & lodging$77,7406%
- Food & beverage$5,3190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $648,206 |
| Boehringer Ingelheim International GmbH | 168 | $244,207 |
| Daiichi Sankyo Inc. | 9 | $167,962 |
| Boehringer Ingelheim | 50 | $65,357 |
| GSK | 21 | $36,352 |
| United Therapeutics Corporation | 40 | $25,683 |
| Astrazeneca UK Limited | 4 | $21,713 |
| Astrazeneca AB | 8 | $16,650 |
| AbbVie | 8 | $13,931 |
| Merck | 14 | $11,157 |
| Amgen | 11 | $11,094 |
| E.r. Squibb & Sons, L.L.C. | 10 | $11,002 |
| Chiesi USA, Inc. | 9 | $10,447 |
| Sanofi-aventis U.S. LLC | 2 | $8,380 |
| F. Hoffmann-la Roche AG | 2 | $7,222 |
| Bristol Myers Squibb | 2 | $4,950 |
| CSL Behring | 3 | $4,445 |
| Shionogi Inc | 2 | $2,975 |
| Lupin Inc. | 1 | $2,655 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,440 |
| Pfizer | 1 | $1,530 |
| Syndax Pharmaceuticals, Inc. | 1 | $750 |
| Roche Products Limited | 1 | $660 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,319,767 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 425 | $5,322,763 |
| EsbrietPirfenidone | 31 | $308,115 |
| Pirfenidone | 113 | $187,544 |
| Dupixent PenDupilumab | 48 | $174,476 |
| Actemra ActpenTocilizumab | 25 | $80,233 |
| XolairOmalizumab | 24 | $44,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $30,161 |
| Mycophenolate Mofetil | 106 | $15,653 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,222 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,282 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $5,583 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $5,486 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $4,925 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $4,168 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $65,357 | $5,333,045445 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $36,352 | $43,38364 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
- Jameel HouraniLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.